Sutro Biopharma Inc (STRO) extends its cash runway and strengthens partnerships while navigating workforce cuts and ...

Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...

Piper Sandler downgraded Sutro Biopharma (STRO) to Neutral from Overweight with a price target of $2, down from $8. The ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as ...

Oppenheimer analyst Jay Olson downgraded Sutro Biopharma (STRO) to Perform from Outperform after the company reported Q4 results and announced ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 million in 2023, and announced a pipeline restructuring.

Sutro Biopharma (STRO) stock drops 14% after deprioritizing ADC program; analysts from Bank of America and Citizens slash ratings in reaction. Read more here.

Sutro Biopharma, Inc.’s STRO share price has dipped by 35.19%, which has investors questioning if this is right time to buy.

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...